Abstract 6690: Monitoring response and resistance to EGFR inhibition with circulating tumor DNA in a non-small cell lung cancer patient-derived xenograft

• Published in: Cancer research (Chicago, Ill.) Ill.), 2023-04, Vol.83 (7_Supplement), p.6690-6690
• Main Authors: Do, Long H., Pippa, Raffaella, Andrews, Warren, Chien, Yuan, Sperry, Jantzen, Nakashima, Jonathan
• Format: Article
• Language: English
• ISSN: 1538-7445; 1538-7445
• DOI: 10.1158/1538-7445.AM2023-6690

Circulating tumor DNA (ctDNA) has been shown as a clinically relevant biomarker for non-invasive monitoring of therapy response, disease burden and disease progression in cancer patients. Patient-derived xenografts (PDX) are essential translational models used for evaluating therapeutic response and identifying novel biomarkers, but analysis of ctDNA in these models remains understudied. Here, we report the use of ctDNA for the monitoring of therapeutic response and secondary resistance of a Non-Small Cell Lung Cancer PDX treated with EGFR inhibitors. We demonstrate measurable ctDNA changes correlate with disease burden and therapeutic response. Altogether, the isolation of ctDNA from PDX models is a robust methodology for interrogating therapeutic efficacy, response, and resistance in a preclinical setting that can be translated as a viable biomarker for non-invasive monitoring in patients. Citation Format: Long H. Do, Raffaella Pippa, Warren Andrews, Yuan Chien, Jantzen Sperry, Jonathan Nakashima. Monitoring response and resistance to EGFR inhibition with circulating tumor DNA in a non-small cell lung cancer patient-derived xenograft. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6690.